Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors

NCT00655655 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT00655655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00655655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2004
Completion date
January 11, 2018
Enrollment
96 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastrinoma, glucagonoma, insulinoma, metastatic gastrointestinal carcinoid tumor, metastatic pheochromocytoma, pancreatic polypeptide tumor, recurrent gastrointestinal carcinoid tumor, recurrent islet cell carcinoma, recurrent melanoma, recurrent neuroendocrine carcinoma of the skin, recurrent non-small cell lung cancer, recurrent pheochromocytoma, recurrent renal cell cancer, somatostatinoma, stage iii neuroendocrine carcinoma of the skin, stage iv melanoma, stage iv non-small cell lung cancer, stage iv renal cell cancer, thyroid gland medullary carcinoma, unspecified adult solid tumor, protocol specific